International Clinical Trial: A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07827573) titled 'A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment' on Sept. 15.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Hoffmann-La Roche

Condition: Early Breast Cancer Estrogen Receptor-Positive Breast Cancer HER2-Negative Breast Cancer

Intervention: Drug: Giredestrant

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First ...